AIM: The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation. METHOD: A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated. RESULTS: Using docetaxel, indium(111) and yttrium(90) as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs. CONCLUSION: We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.
AIM: The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation. METHOD: A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated. RESULTS: Using docetaxel, indium(111) and yttrium(90) as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs. CONCLUSION: We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.
Authors: Omid C Farokhzad; Sangyong Jon; Ali Khademhosseini; Thanh-Nga T Tran; David A Lavan; Robert Langer Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: Moses O Oyewumi; Robert A Yokel; Michael Jay; Tricia Coakley; Russell J Mumper Journal: J Control Release Date: 2004-03-24 Impact factor: 9.776
Authors: O W Press; D Shan; J Howell-Clark; J Eary; F R Appelbaum; D Matthews; D J King; A M Haines; P Hamann; L Hinman; D Shochat; I D Bernstein Journal: Cancer Res Date: 1996-05-01 Impact factor: 12.701
Authors: A Gabizon; R Chisin; S Amselem; S Druckmann; R Cohen; D Goren; I Fromer; T Peretz; A Sulkes; Y Barenholz Journal: Br J Cancer Date: 1991-12 Impact factor: 7.640
Authors: Diana Dehaini; Ronnie H Fang; Brian T Luk; Zhiqing Pang; Che-Ming J Hu; Ashley V Kroll; Chun Lai Yu; Weiwei Gao; Liangfang Zhang Journal: Nanoscale Date: 2016-07-14 Impact factor: 7.790
Authors: Michael E Werner; Shrirang Karve; Rohit Sukumar; Natalie D Cummings; Jonathan A Copp; Ronald C Chen; Tian Zhang; Andrew Z Wang Journal: Biomaterials Date: 2011-08-16 Impact factor: 12.479
Authors: Allison N DuRoss; Megan J Neufeld; Shushan Rana; Charles R Thomas; Conroy Sun Journal: Adv Drug Deliv Rev Date: 2019-07-04 Impact factor: 15.470